Dipyridamole may block COVID-19 induced blood clotting and inflammation firestorms.

Key Messages

COVID-19 affects multiple body systems, and the cytokine storm it causes results in hypercoagulation and uncontrolled inflammation.

The body uses a signaling system known as the “purinergic system” to control inflammation and blood clotting activity.

The drug dipyridamole is known to increase the bioavailability of adenosine, which is one of the “purinergic system” messengers.

This article discusses using dipyridamole as a potential treatment to reduce COVID-19 severity by targeting purinergic signaling, thereby reducing inflammation and hyper blood clotting activity.

JCI Insight

Publication Date: July 23, 2021
Peer Reviewed: No
Publication Type: Review/Commentary/Letter
DOI: https://www.doi.org/10.1172/jci.insight.140971

New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm

Yogendra Kanthi, Jason S. Knight, Yu Zuo, David J. Pinsky

Abstract

Purinergic signaling is discussed as a potential therapeutic target to reduced COVID-19 severity.